LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・Amarin Corp PLC ADR

Amarin Corp PLC ADR

Cerrado

0.59 -1.67

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.58

Máximo

0.6

Métricas clave
By Trading Economics
Ingresos	11M 1.5M
Ventas	11M 67M
BPA	0.01
Margen de beneficio	2.252
EBITDA	13M 237K

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 meses	+66.67 upside

Dividendos
By Dow Jones
Próximas Ganancias	30 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	8M 257M
Apertura anterior	2.26
Cierre anterior	0.59

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.6001 / 0.61 Soporte y Resistencia

Amarin Corp PLC ADR Gráfico

Noticias Relacionadas

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept 2024, 18:15 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept 2024, 18:12 UTC

Principales Noticias

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept 2024, 17:44 UTC

Charlas de Mercado

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept 2024, 17:30 UTC

Charlas de Mercado

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept 2024, 17:30 UTC

Principales Noticias

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept 2024, 17:27 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept 2024, 17:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 sept 2024, 17:00 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in August -- Market Talk

6 sept 2024, 16:36 UTC

Charlas de Mercado

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept 2024, 16:35 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept 2024, 16:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept 2024, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

6 sept 2024, 16:20 UTC

Ganancias

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept 2024, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Amarin Corp PLC ADR Esperado

Precio Objetivo

By TipRanks

66.67% repunte

Estimación a 12 meses

Media 1 USD 66.67%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amarin Corp PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Amarin Corp PLC ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6001 / 0.61Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.